These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17671204)

  • 21. Inducing Polyclonal Eag1-Specific Antibodies by Vaccination with a Linear Epitope Immunogen and Its Relation to Breast Tumorigenesis.
    Li Z; Zhu K; Gong X; Vasilescu S; Sun Y; Hong K; Li H; Li L; Shan Y
    Pathol Oncol Res; 2017 Oct; 23(4):761-767. PubMed ID: 28070819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potassium channels as tumour markers.
    Stühmer W; Alves F; Hartung F; Zientkowska M; Pardo LA
    FEBS Lett; 2006 May; 580(12):2850-2. PubMed ID: 16783874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Zachariae U; Giordanetto F; Leach AG
    J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eag1 Voltage-Dependent Potassium Channels: Structure, Electrophysiological Characteristics, and Function in Cancer.
    Wang X; Chen Y; Zhang Y; Guo S; Mo L; An H; Zhan Y
    J Membr Biol; 2017 Apr; 250(2):123-132. PubMed ID: 28160046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo imaging of tumour xenografts with an antibody targeting the potassium channel K
    Napp J; Pardo LA; Hartung F; Tietze LF; Stühmer W; Alves F
    Eur Biophys J; 2016 Oct; 45(7):721-733. PubMed ID: 27444284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Derlin-1 is overexpressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy.
    Ran Y; Hu H; Hu D; Zhou Z; Sun Y; Yu L; Sun L; Pan J; Liu J; Liu T; Yang Z
    Clin Cancer Res; 2008 Oct; 14(20):6538-45. PubMed ID: 18927294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional expression of the voltage-gated neuronal mammalian potassium channel rat ether à go-go1 in yeast.
    Schwarzer S; Kolacna L; Lichtenberg-Fraté H; Sychrova H; Ludwig J
    FEMS Yeast Res; 2008 May; 8(3):405-13. PubMed ID: 18248412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD31 delays phagocyte membrane repolarization to promote efficient binding of apoptotic cells.
    Vernon-Wilson EF; Auradé F; Tian L; Rowe IC; Shipston MJ; Savill J; Brown SB
    J Leukoc Biol; 2007 Nov; 82(5):1278-88. PubMed ID: 17684043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
    Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
    Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eag1 K
    Han B; Tokay T; Zhang G; Sun P; Hou S
    Oxid Med Cell Longev; 2017; 2017():7371010. PubMed ID: 28367272
    [No Abstract]   [Full Text] [Related]  

  • 32. Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.
    Myokai T; Ryu S; Shimizu H; Oiki S
    Mol Pharmacol; 2008 Jun; 73(6):1643-51. PubMed ID: 18326583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels.
    Zhang DY; Wang Y; Lau CP; Tse HF; Li GR
    Cell Signal; 2008 Oct; 20(10):1815-21. PubMed ID: 18617000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo dual targeting of the oncogenic Ether-à-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors.
    García-Quiroz J; García-Becerra R; Santos-Martínez N; Barrera D; Ordaz-Rosado D; Avila E; Halhali A; Villanueva O; Ibarra-Sánchez MJ; Esparza-López J; Gamboa-Domínguez A; Camacho J; Larrea F; Díaz L
    BMC Cancer; 2014 Oct; 14():745. PubMed ID: 25280486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
    Van Aarsen LA; Leone DR; Ho S; Dolinski BM; McCoon PE; LePage DJ; Kelly R; Heaney G; Rayhorn P; Reid C; Simon KJ; Horan GS; Tao N; Gardner HA; Skelly MM; Gown AM; Thomas GJ; Weinreb PH; Fawell SE; Violette SM
    Cancer Res; 2008 Jan; 68(2):561-70. PubMed ID: 18199553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond hemostasis: a snake venom serine protease with potassium channel blocking and potential antitumor activities.
    Boldrini-França J; Pinheiro-Junior EL; Peigneur S; Pucca MB; Cerni FA; Borges RJ; Costa TR; Carone SEI; Fontes MRM; Sampaio SV; Arantes EC; Tytgat J
    Sci Rep; 2020 Mar; 10(1):4476. PubMed ID: 32161292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia.
    Agarwal JR; Griesinger F; Stühmer W; Pardo LA
    Mol Cancer; 2010 Jan; 9():18. PubMed ID: 20105281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment.
    Toplak Ž; Hendrickx LA; Abdelaziz R; Shi X; Peigneur S; Tomašič T; Tytgat J; Peterlin-Mašič L; Pardo LA
    Med Res Rev; 2022 Jan; 42(1):183-226. PubMed ID: 33945158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.